Can.Heal high-level stakeholder Conference

There are many ways to refer to the subject of the High Level Conference that will address two
flagships of the European Beating Cancer Plan which are ‘Access and Diagnostics for All’ as
well as Public Health Genomic. The conference will be held in Rome on April 26th and 27th.

World Cancer Day 2023.

Cancer can affect everyone, regardless of age, gender or social status and puts immense pressure on European health systems. Fighting cancer is one of the priorities of the European Health Union. Delivering better long-term care for patients living with cancer also means reducing significant disparities, both between and within Member States. World Cancer Day, marked […]

Pushing the agenda in the field of cancer – EAPM ready to respond

Announcement: European Parliament Cancer Event on February 7th:  Pushing the agenda in the field of cancer – EAPM ready to respond Brussels, January 24th, 2023: Greetings all, the European Alliance for Personalised Medicine will be holding an event in the European Parliament entitled ‘Early Diagnosis unfulfilled – Propelling early Diagnosis into the twenties for Cancer Patients’ on […]

WP14 Healthcare system implementation

objectives: WP14’s primary purpose is to create recommendations to assist public health authorities in implementing personalized approaches to cancer prevention, diagnosis, and treatment within the EU healthcare systems. Evidence and mapping analyses completed in various WPS will be synthesised in order to provide a comprehensive picture of the most recent research advances in personalised approaches […]

WP13 Training and education

Objectives: We aim at laying the groundwork for a training platform that will address multiple challenges and training needs and literacy of healthcare professionals, patients and the general public. By providing specific education and training for health workers, we hope to advance the implementation and increase the use of genetic testing in oncology. Additionally, we […]

WP12 Law, ethics and citizen engagement

objective:Developing legal, ethical and trust frameworks for clinical and public health cancer genomics. The primary focus of WP12 is on developing legal, ethical and trust frameworks for clinical and public health cancer genomics. With the shift towards routine genomic sequencing in healthcare and prevention contexts, there will be significant opportunities to re-use this data beyond […]

WP11 NGS including Liquid Biopsy

Objectives: This working package is focusing on implementation of NGS-based and liquid biopsy assays in clinical practice. Our aims are establishing a quality management system for NGS-based clinical assays and standardizing assay-reporting outcomes to facilitate data harmonization across the EU. We will develop recommendations, guidelines, and best practices to move the clinical implementation of NGS […]

WP10 Oncology Decision Support Tools

Use cases: cBioPortal, DIGICORE, oncNGS, HARMONY, BALLETT, GERSOM, EOLUNG objectives: The primary goal of this WP is to optimize and harmonize tools for data integration (genomic and clinical data) and decision support (MTB and treatment) in order to speed up and standardize the process of diagnosing and treating cancer. This will be accomplished by mapping […]

WP9 Treatment and follow-up

Objectives: Aim of this working package is to evaluate the clinical value of Comprehensive Genomic Profiling (CGP) in “real-world” practice for offering more therapeutic options to cancer patients and a broader access to precision oncology. We will evaluate the feasibility of implementing a fully standardized CGP wet-lab performance, data analysis, clinical interpretation, therapy recommendation and […]

WP8 Diagnosis and treatment decision via MTB (molecular tumor boards)

objectives: Non-standardized variant interpretation and many simultaneous mutations in the cancer genome cause therapy inconsistency and injustice. With the growing number of targeted medicines approved in oncology for the same reason and the complexity of tumor profiles, molecular screening programs have been further incorporated in clinical routine to simplify access to matching therapies via Molecular […]

WP7 Prevention and early detection

Objectives: A shared EU vision for how to combat cancer as early as possible in the clinical history will be developed, and the Damocles’ sword of minimal residual disease that weighs on patients’ and their families’ heads will be addressed. When tools are needed for selective therapy intensification in high-risk patients or treatments that have […]

WP6 Building Clinical utility

objectives: Clinical utility typically refers to the usefulness or utility of a finding, practice, or technology for clinical or medical objectives. WP6 will provide a map of clinical utility evidences for cancer, as well as evaluation metrics. To illustrate the clinical utility of Public Health Genomics (PHG), we will pilot and assess clinical value for […]